70024-40-7

Basic information

• Product Name: Terazosin hydrochloride dihydrate
• Synonyms: arbonyl)-,monohydrochloride,dihydrate;Hytrinex;iperazinehcl2h2o;TERAZOSIN HCL 2H2O;TERAZOSIN HYDROCHLORIDE DIHYDRATE;TERAZOSIN MONOHYDROCHLORIDE DIHYDRATE;Terazosin HCL dihydrate;TerazosinHclC19H26C1N504
• CAS NO: 70024-40-7
• Molecular Formula: C19H30ClN5O6
• Molecular Weight: 459.92
• EINECS: 1533716-785-6
• Product Categories: Active Pharmaceutical Ingredients;Antihypertensive;Inhibitors;API
• Mol File: 70024-40-7.mol
• Article Data: 5

Chemical Properties

• Melting Point: 271-274°C
• Boiling Point: 664.5 °C at 760 mmHg
• Flash Point: 355.7 °C
• Appearance: /
• Vapor Pressure: 1.59E-17mmHg at 25°C
• Storage Temp.: Sealed in dry,Room Temperature
• Solubility: Sparingly soluble in water, slightly soluble in methanol, very slightly soluble in ethanol (96 per cent), practically insoluble in acetone.
• CAS DataBase Reference: Terazosin hydrochloride dihydrate(CAS DataBase Reference)
• NIST Chemistry Reference: Terazosin hydrochloride dihydrate(70024-40-7)
• EPA Substance Registry System: Terazosin hydrochloride dihydrate(70024-40-7)

Safety Data

• Hazard Codes: Xn
• Statements: 22
• RTECS: TK8046000
• Hazardous Substances Data: 70024-40-7(Hazardous Substances Data)

Usage

Uses

Terazosin Hydrochloride Dihydrate is an α-1-adrenergic blocker related to prazosin.

Manufacturing Process

To a solution of n-butanol (316 ml), water (24 ml) and N-(2- tetrahydrofuroyl)piperazine (20 g) were added, while stirring, 4-amino-2- chloro-6,7-dimethoxyquinazoline (22.2 g). The reaction mixture was heated to reflux and the reflux was maintained for about 9 h. Then the reaction mixture was cooled to room temperature and stirred at this temperature for about 10- 12 h. The crystals were collected by filtration, washed with n-BuOH and dried in vacuo at 40-50°C to yield 40.1 g (94%) of the 1-(4-amino-6,7-dimethoxy- 2-quinazolinyl)-4-(tetrahydrofuroyl)piperazine hydrochloride dihydrate

Therapeutic Function

Antihypertensive

InChI:InChI=1/C19H25N5O4.ClH.2H2O/c1-26-15-10-12-13(11-16(15)27-2)21-19(22-17(12)20)24-7-5-23(6-8-24)18(25)14-4-3-9-28-14;;;/h10-11,14H,3-9H2,1-2H3,(H2,20,21,22);1H;2*1H2

Upstream product

• 67-63-0 isopropyl alcohol 
• 23680-84-4 2-chloro-6,7-dimethoxyquinazolin-4-amine 
• 63074-07-7 N-(tetrahydro-2-furoyl)-piperazine 

Relevant articles and documents

COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING SALT SENSITIVITY OF BLOOD PRESSURE

To characterize the urinary exosome miRNome, microarrays were used to identify the miRNA spectrum present within urinary exosomes from ten individuals that were previously classified for their salt sensitivity status. The present application discloses distinct patterns of selected exosomal miRNA expression that were different between salt-sensitive (SS), salt-resistant (SR), and inverse salt-sensitive (ISS) individuals. These miRNAs can be useful as biomarkers either individually or as panels comprising multiple miRNAs. The present invention provides compositions and methods for identifying, diagnosing, monitoring, and treating subjects with salt sensitivity of blood pressure. The applications discloses panels of miRNAs useful for comparing profiles, and in some cases one or more of the miRNAs in a panel can be used. The miRNAs useful for distinguishing SS and SR or ISS and SR subjects. One or more of the 45 miRNAs can be used. Some of the miRNAs have not been previously reported to be circulating. See those miRNAs with asterisks in FIG. 1 and below. The present invention encompasses the use of one or more of these markers for identifying and diagnosing SR, SS, and ISS subjects.

Terazosin crystalline polymorph and pharmaceutical compositions thereof

The present invention relates to the discovery of novel polymorph form of an active pharmaceutical agent and the process for its preparation. More specifically, the present invention relates to the preparation of a novel polymorph form of terazosin hydrochloride, a well known anti-hypertensive agent.

Terazosin monohydrochloride and processes and intermediate for its production

The present invention provides a non-solvated crystalline polymorph of terazosin monohydrochloride designated Form III and methods for its preparation. Also disclosed is terazosin monohydrochloride methanolate and processes for its production as well as processes for its conversion to other crystalline forms of terazosin monohydrochloride.